Butterfly Network

Butterfly Network develops portable ultrasound systems such as the iQ3 that enable whole-body diagnostics via smartphone and AI-assisted image analysis. On September 22, Needham’s “Buy” rating and $10 price target, together with accelerated adoption of the company’s own AI platform, triggered a massive surge in the share price. The company continues to focus on miniaturization and AI to scale usage in hospitals and care settings. » Más en finanzen.net

Butterfly Network has signed a multi-year license agreement with Merge Labs that gives Merge access to the Poseidon family of Ultrasound-on-Chip technology through Butterfly Embedded, Butterfly’s licensing business. Merge Labs plans to use the semiconductor-based ultrasound platform to develop ultrasound-enabled brain-computer interfaces. The agreement includes upfront and milestone payments, hardware purchase commitments, and ongoing royalties on future revenues; Butterfly will be the exclusive partner for Merge’s CMOS‑MEMS chip‑based ultrasound technology but reserves the right to grant additional licenses. » Más en de.investing.com

The stock of Butterfly Network rose to a 52-week high of $9.74 and is currently trading around $9.77, implying a market capitalization of about $2.57 billion and a 1-year performance of +601.47%. Data from InvestingPro view the stock as significantly above its fair value and point to a high beta of 2.08, indicating considerable volatility. In Q2 2026 the company reported adjusted EPS of -$0.01 (better than expected) on revenue of $15.72 million (below expectations), but raised its full-year outlook and highlighted a record quarter with stronger margins and higher US sales. » Más en de.investing.com